Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Repinotan · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | - |
| Arm 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Repinotan HCl (BAYX3702) | DRUG | All patients receive 1.25 mg of repinotan |
| Placebo | DRUG | All patients receive 1.25 mg of placebo |
Inclusion Criteria: * Acute ischemic stroke of hemispheric localization (exclude brainstem and cerebellum), of suspected thromboembolic origin. * Males or females aged 18 years or over. * National Institute of Health Stroke Scale (NIH-SS) total score 8 to 23 with a motor deficit \>/= 2 (for either ...
Top 20 of 24 competitors
Repinotan is an investigational small molecule being developed for the treatment of stroke, specifically acute ischemic stroke. It is a neurology therapeutic that has been studied in a Phase 2 clinical trial. Repinotan is not approved and remains in clinical development.
Repinotan is being developed by Bayer AG, a pharmaceutical company traded on the OTC market under the ticker BAYRY. The drug is an investigational small molecule intended for the treatment of acute ischemic stroke.
Repinotan is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug is investigational and has not been approved for any use.
Repinotan has been studied in one completed Phase 2 trial, NCT00044915, titled "Repinotan in Patients With Acute Ischemic Stroke." This trial enrolled 782 participants across multiple countries, including the United States, Australia, and several European nations.
No alternative names for Repinotan have been reported. The drug is known by the single name Repinotan and is being developed by Bayer AG for the treatment of acute ischemic stroke.